“…β 2 -adrenoceptors activate adenylate cyclase that results in increased intracellular cAMP levels and activation of protein kinase A (PKA), which in turn regulates phosphorylation (activation) of target molecules and gene expression. Table 1 Primer and probe sequences Primer Sequence mTTP forward 5′-CTCAGAAAGCGGGCGTTGT-3′ mTTP reverse 5′-GATTGGCTTGGCGAAGTTCA-3′ mTTP probe 5′-Fam-CCAAGTGCCAGTTTGCTCACGGC-Tamra-3′ mGAPDH forward 5′-GCATGGCCTTCCGTGTTC-3′ mGAPDH reverse 5′-GATGTCATCATACTTGGCAGGTTT-3′ mGAPDH probe 5′-Fam-TCGTGGATCTGACGTGCCGCC-Tamra-3′ hTTP forward 5′-CCCCAAATACAAGACGGAACTC-3′ hTTP reverse 5′-GGGCCGCCAGGTCTTC-3′ hTTP probe 5′-Fam-CCCTACGGCTCTCGCTGCCACTT-Tamra-3′ hGAPDH forward 5′-AAGGTCGGAGTCAACGGATTT-3′ hGAPDH reverse 5′-GCAACAATATCCACTTTACCAGAGTTAA-3′ hGAPDH probe 5′-Fam-CGCCTGGTCACCAGGGCTGC-Tamra-3′ β 2 -agonists have been shown to inhibit TNF-α and GM-CSF release from human mast cells, blood monocytes, macrophages, lyphocytes, and epithelial cells, and demonstrate their anti-inflammatory effects possibly through elevation of cAMP levels (Bissonnette and Befus, 1997;Broadley, 2006;Izeboud et al, 1999;Johnson, 2002;Sitkauskiene and Sakalauskas, 2005). There is tentative data that an activator of adenylate cyclase, forskolin, and an analog of cAMP, dibutyryl-cAMP, may increase TTP mRNA levels (DuBois et al, 1990;Kaneda et al, 1992).…”